

Claims:

The applicant claims the following:

- 21.** A mono amine oxidase inhibitor hydrazide drug shuts down ongoing protein biosynthesis in cells which provides the method used to inhibit proteins including oxidase for antidepressant uses until the cell succumbs to apoptosis and is replaced, wherein improvements that provide a different purpose comprises the same method to shutdown ongoing protein biosynthesis in cells to inhibit metastatic or disease related proteins that likewise follows with apoptosis and cell replacements that are free of disease or DNA damage.
- 22.** A method for targeting and eradicating diseased cells that are producing metastatic or disease related protein products for a patient in need thereof comprising the administering of a pharmaceutical preparation of a mono amine oxidase inhibitor hydrazide drug in an amount effective to shutdown ongoing protein biosynthesis thereby inducing apoptosis and cell replacement with new cells that are free of disease or DNA damage.
- 23.** The method of claim 1 and 2 where said diseased cells are replaced with cancerous cells, viral infected cells, and DNA damaged cells.
- 24.** A method for antibiotic adjuvant use comprising the administering of a pharmaceutical preparation of a mono amine oxidase inhibitor hydrazide concurrent with antibiotic therapy sufficient to render microorganisms vulnerable to antibiotic action by inhibiting microorganism protein biosynthesis of enzymes that would metabolize, detoxify, block, or repair damage done by the antibiotic action, and that likewise inhibits peptide biosynthesis used to induce cell division and growth, and hence proliferation which serves to render the microorganisms sterile and without progeny to pass on any antibiotic resistance traits that may evolve.
- 25.** The method of claim 1, 2 and 4 where a mono amine oxidase inhibitor hydrazide drug is replaced with Iproniazid, Isocarboxazid, Nialamide, and any irreversible substrate hydrazide.